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Two-component mRNA-based vaccine (RNActive®)
combines high antigen expression with strong immune
stimulation. We have previously shown that intradermal
administration of RNActive® vaccines induced balanced,
potent and long-lasting immune responses in both mice
and humans. Here, we characterized in detail early
events after vaccine injection to better understand the
self-adjuvant capacity of mRNA-based vaccines. Shortly
after intradermal administration, mRNA was present in
both non-leukocytic and leukocytic cells, the latter being
mostly represented by MHC class II-expressing cells.
Further studies revealed that 24 h after intradermal
administration RNActive® was detectable in dendritic
cells (DCs) within the draining lymph nodes (dLNs).
Full genome microarray analyses of the skin tissues
showed that RNActive® vaccine transiently altered the
gene expression profile at the injection site. Various che-
mokines such as CXCR3 ligands (including CXCL9,
CXCL10 and CXCL11) as well as CCL2, CCL4, CCL5
and CCL12, whose pleiotropic functions include recruit-
ment and activation of macrophages, NK cells and DCs,
were up-regulated early after RNActive® treatment.
Additionally, gene expression of multiple proinflamma-
tory cytokines such as IL-6 or TNF-a was increased. In
corroboration with the microarray data, after injection
of mRNA vaccine we observed a strong production of
chemokines including CXCL9, CXCL10, CCL3, CCL4,
CCL5 as well as proinflamatory cytokines (IL-6, TNF-a)
at the site of injection. No changes in the cytokine
serum level were detected suggesting a local immunosti-
mulation with no signs of cytokine release syndrome.
The innate immune responses in the skin were followed
by the increased cellularity as well as an enhanced acti-
vation of a wide range of the immune cells in the dLNs
including CD8+ T-cells, B cells, gδ T-cells, NK and NKT
cells. In summary, our data indicate that the self-
adjuvanted RNActive® vaccine induces strong innate
immune response at the site of administration followed
by the activation of the immune cells in the dLNs.
These results provide a possible mechanistic explanation
of a potent and balanced adaptive immunity induced by
mRNA-based vaccine which is a novel vaccination plat-
form for an efficient cancer immunotherapy.
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